Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Georgy JT, Singh A, John AO, Joel A, Andrews AG, Thumaty DB, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Backianathan S, Chacko RT.
Georgy JT, et al. Among authors: joel a.
Klin Onkol. 2021 Winter;34(1):49-55. doi: 10.48095/ccko202149.
Klin Onkol. 2021.
PMID: 33657819
English.